Stockscreener 앱 받기
9.58
0.62%
-0.06
시간 외 거래:
9.58
전일 마감가:
$9.64
열려 있는:
$9.62
하루 거래량:
1.70M
Relative Volume:
0.74
시가총액:
$2.86B
수익:
$493.67M
순이익/손실:
$-104.69M
주가수익비율:
-28.18
EPS:
-0.34
순현금흐름:
$-31.51M
1주 성능:
-0.31%
1개월 성능:
+1.70%
6개월 성능:
-7.08%
1년 성능:
-22.93%
1일 변동 폭
$9.555
$9.73
1주일 범위
$9.465
$9.83
52주 변동 폭
$8.785
$14.03
아미쿠스 테라 Stock (FOLD) Company Profile
명칭
Amicus Therapeutics Inc
전화
(609) 662-2000
주소
47 HULFISH STREET, PRINCETON, NJ
FOLD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FOLD
Amicus Therapeutics Inc
|
9.58 | 2.86B | 493.67M | -104.69M | -31.51M | -0.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
아미쿠스 테라 Stock (FOLD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-13 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-09-06 | 개시 | Jefferies | Buy |
| 2024-05-30 | 개시 | Wells Fargo | Overweight |
| 2024-05-14 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-12-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-09-09 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-04-13 | 재개 | Goldman | Neutral |
| 2022-01-14 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-15 | 업그레이드 | Stifel | Hold → Buy |
| 2021-09-30 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-07-19 | 재개 | BTIG Research | Buy |
| 2021-05-27 | 개시 | Needham | Hold |
| 2021-05-21 | 개시 | UBS | Buy |
| 2021-04-14 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2021-03-02 | 개시 | Stifel | Hold |
| 2021-02-12 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-12 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-12-28 | 재개 | Cantor Fitzgerald | Overweight |
| 2020-12-10 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-11-11 | 개시 | Berenberg | Hold |
| 2020-06-17 | 개시 | BTIG Research | Buy |
| 2020-02-04 | 재개 | Cantor Fitzgerald | Overweight |
| 2019-11-12 | 재확인 | H.C. Wainwright | Buy |
| 2019-06-17 | 개시 | H.C. Wainwright | Buy |
| 2019-06-05 | 재확인 | Cantor Fitzgerald | Overweight |
| 2019-04-05 | 개시 | Janney | Buy |
| 2019-01-30 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-10-29 | 개시 | Citigroup | Neutral |
| 2018-08-17 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2017-10-06 | 재개 | Goldman | Neutral |
| 2017-09-13 | 재확인 | Chardan Capital Markets | Buy |
| 2017-08-10 | 재확인 | Chardan Capital Markets | Buy |
| 2017-01-24 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2016-05-18 | 개시 | BofA/Merrill | Buy |
| 2016-04-14 | 개시 | Robert W. Baird | Neutral |
| 2016-04-12 | 재확인 | Chardan Capital Markets | Buy |
| 2015-09-16 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2015-06-16 | 재확인 | Chardan Capital Markets | Buy |
모두보기
아미쿠스 테라 주식(FOLD)의 최신 뉴스
Amicus Therapeutics (NASDAQ:FOLD) shareholders have endured a 26% loss from investing in the stock a year ago - Simply Wall St
13,028 Shares in Amicus Therapeutics, Inc. (NASDAQ:FOLD) Acquired by Park Avenue Securities LLC - Defense World
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by Inspire Investing LLC - MarketBeat
Amicus Therapeutics expects 2024 revenue slightly above consensus, guides 2025 - MSN
Leerink Partnrs Issues Optimistic Estimate for FOLD Earnings - MarketBeat
Research Analysts Set Expectations for FOLD Q2 Earnings - MarketBeat
Assenagon Asset Management S.A. Has $4.49 Million Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Assenagon Asset Management S.A. Reduces Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World
Is Amicus Therapeutics (FOLD) Among Billionaire Joseph Edelman’s Long-Term Stock Picks? - Insider Monkey
Amicus Therapeutics, Inc. (FOLD): The Biotech Stock with Biggest Upside Potential - Yahoo Finance
Jefferies Initiates Coverage of Amicus Therapeutics (FOLD) with Buy Recommendation - MSN
Cantor Fitzgerald Reaffirms Overweight Rating for Amicus Therapeutics (NASDAQ:FOLD) - Defense World
Amicus Therapeutics (NASDAQ:FOLD) Earns Overweight Rating from Cantor Fitzgerald - MarketBeat
Enzyme Replacement Therapy Market Deep Research Report with - openPR
When (FOLD) Moves Investors should Listen - Stock Traders Daily
Analysts Set Amicus Therapeutics, Inc. (NASDAQ:FOLD) Price Target at $16.88 - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Average Rating of “Moderate Buy” by Analysts - Defense World
Amicus Posts Preliminary 2024 Results, Issues 2025 Outlook - MSN
Amicus Therapeutics (NASDAQ:FOLD) Shares Gap UpStill a Buy? - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Earns Hold Rating from Needham & Company LLC - MarketBeat
A Glimpse Into The Expert Outlook On Amicus Therapeutics Through 6 Analysts - Benzinga
Shareholders in Amicus Therapeutics (NASDAQ:FOLD) have lost 32%, as stock drops 3.0% this past week - Yahoo Finance
Fabry Disease Treatment Market Top Companies StudySanofi SA, - openPR
Amicus Therapeutics Reports Preliminary 2024 Revenue and Provides 2025 Strategic Outlook - GlobeNewswire
Amicus Therapeutics Reports Stellar 32% Revenue Growth to $528.5M, Eyes $1B Sales Target - StockTitan
Is Amicus Therapeutics (FOLD) the Best Medical Stock to Buy Under $20? - Insider Monkey
12 Best Medical Stocks To Buy Under $20 - Insider Monkey
Amicus Therapeutics stock hits 52-week low at $9.01 By Investing.com - Investing.com Canada
Amicus Therapeutics (NASDAQ:FOLD) Reaches New 1-Year LowShould You Sell? - MarketBeat
Amicus Therapeutics stock hits 52-week low at $9.01 - Investing.com
Principal Financial Group Inc. Reduces Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by Principal Financial Group Inc. - MarketBeat
How the (FOLD) price action is used to our Advantage - Stock Traders Daily
Amicus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Amicus Therapeutics CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
JPMorgan Chase & Co. Sells 1,984,751 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Holdings Trimmed by JPMorgan Chase & Co. - Defense World
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Short Interest Update - MarketBeat
Investors Aren't Buying Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Revenues - Simply Wall St
Amicus Therapeutics: Cheap Heading Into 2025 (NASDAQ:FOLD) - Seeking Alpha
Stifel Financial Corp Sells 21,615 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World
Geode Capital Management LLC Acquires 80,926 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Fabry Disease Treatment Market Growth in Future Scope 2024-2031 - openPR
아미쿠스 테라 (FOLD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.95%
2.39%
자본화:
|
볼륨(24시간):